Celon Pharma SA

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: PLCLNPH00015
PLN
19.98
-0.02 (-0.1%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Poor Management Efficiency with a low ROE of 1.43%

  • The company has been able to generate a Return on Equity (avg) of 1.43% signifying low profitability per unit of shareholders funds
2

Poor long term growth as Operating profit has grown by an annual rate -17.49% of over the last 5 years

 
3

With ROE of -0.77%, it has a risky valuation with a 3.08 Price to Book Value

4

Below par performance in long term as well as near term

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

PLN 1,088 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.03

stock-summary
Return on Equity

1.10%

stock-summary
Price to Book

2.80

Revenue and Profits:
Net Sales:
49 Million
(Quarterly Results - Mar 2025)
Net Profit:
-25 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-10.4%
0%
-10.4%
6 Months
-13.51%
0%
-13.51%
1 Year
-16.92%
0%
-16.92%
2 Years
22.58%
0%
22.58%
3 Years
25.66%
0%
25.66%
4 Years
-36.06%
0%
-36.06%
5 Years
-51.56%
0%
-51.56%

Celon Pharma SA for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
17.90%
EBIT Growth (5y)
-17.49%
EBIT to Interest (avg)
-10.38
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.10
Sales to Capital Employed (avg)
0.46
Tax Ratio
23.15%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
1.17%
ROE (avg)
1.43%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.08
EV to EBIT
-1158.12
EV to EBITDA
23.37
EV to Capital Employed
3.23
EV to Sales
4.22
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-0.14%
ROE (Latest)
-0.77%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bearish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Mar 2025 is 35.81% vs -7.63% in Mar 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Mar 2025 is -59.87% vs -65.26% in Mar 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "49.30",
          "val2": "36.30",
          "chgp": "35.81%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-5.30",
          "val2": "-9.10",
          "chgp": "41.76%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.50",
          "val2": "17.80",
          "chgp": "-97.19%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.10",
          "val2": "3.00",
          "chgp": "-96.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-25.10",
          "val2": "-15.70",
          "chgp": "-59.87%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-377.00%",
          "val2": "-601.00%",
          "chgp": "22.40%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 7.66% vs 2.71% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -22.42% vs 28.50% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "179.80",
          "val2": "167.00",
          "chgp": "7.66%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-27.80",
          "val2": "-26.80",
          "chgp": "-3.73%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "2.50",
          "val2": "2.70",
          "chgp": "-7.41%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "5.70",
          "val2": "8.50",
          "chgp": "-32.94%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-34.40",
          "val2": "-28.10",
          "chgp": "-22.42%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-443.10%",
          "val2": "-459.90%",
          "chgp": "1.68%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Mar'25 - YoYstock-summary
Mar'25
Mar'24
Change(%)
Net Sales
49.30
36.30
35.81%
Operating Profit (PBDIT) excl Other Income
-5.30
-9.10
41.76%
Interest
0.50
17.80
-97.19%
Exceptional Items
0.10
3.00
-96.67%
Consolidate Net Profit
-25.10
-15.70
-59.87%
Operating Profit Margin (Excl OI)
-377.00%
-601.00%
22.40%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Mar 2025 is 35.81% vs -7.63% in Mar 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Mar 2025 is -59.87% vs -65.26% in Mar 2024

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
179.80
167.00
7.66%
Operating Profit (PBDIT) excl Other Income
-27.80
-26.80
-3.73%
Interest
2.50
2.70
-7.41%
Exceptional Items
5.70
8.50
-32.94%
Consolidate Net Profit
-34.40
-28.10
-22.42%
Operating Profit Margin (Excl OI)
-443.10%
-459.90%
1.68%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 7.66% vs 2.71% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -22.42% vs 28.50% in Dec 2023

stock-summaryCompany CV
About Celon Pharma SA stock-summary
stock-summary
Celon Pharma SA
Pharmaceuticals & Biotechnology
Celon Pharma SA is a Poland-based company primarily engaged in the pharmaceuticals manufacture. The Company focuses on research, development and production of generic drugs for cancer, neurological diseases, diabetes and other metabolic disorders treatment, among others. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir and Valzek, as well as inhalation powder, such as Salmex. The Company's research center develops pharmaceuticals within a number of therapeutic areas, including oncology, neurology, as well as inflammatory and metabolic diseases. The Company is a subsidiary of Glatton sp z o o.
Company Coordinates stock-summary
Company Details
Ul. Ogrodowa 2A, Kielpin , None : 05-092
stock-summary
Tel: 48 22 751593348 519 066531
stock-summary
Registrar Details